November 3, 2020 10:21 AM EST
R&D
FDA+

PS: Did any­one at Bio­gen ask the FDA to pull an ad­u­canum­ab con­sci­en­tious ob­jec­tor off their ex­pert pan­el? ‘No com­ment’

John Carroll

Editor & Founder

Yes­ter­day I re­port­ed that Bio­gen had dodged a bul­let when the FDA re­cused long­time Alzheimer’s re­searcher David Knop­man from this week’s ex­pert pan­el re­view …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times